Literature DB >> 20043348

Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern.

Bo Zhang1, Qiu-ping Xie, Shun-liang Gao, Yan-biao Fu, Yu-lian Wu.   

Abstract

Somatostatinoma is a very rare neuroendocrine tumor that originates from D cells and accounts for less than 1% of all gastrointestinal endocrine tumors. The duodenum is the most frequent site for this tumor, followed by the pancreas. We here describe a 46-year-old Chinese woman who developed pancreatic somatostatinoma presenting with the characteristic "inhibitory" syndrome, but the symptoms were obscure and seemingly uncorrelated. This case is also unique for its large tumor size and mixed pathological pattern. Distal pancreatectomy was performed, and the patient has remained well since operation. As the syndromes of somatostatinoma may be obscure and atypical, clinicians should review all clinical findings to obtain an accurate diagnosis. Aggressive surgery is preferred to improve the survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043348      PMCID: PMC2801086          DOI: 10.1631/jzus.B0900166

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  23 in total

Review 1.  Somatostatinomas, PPomas, neurotensinomas.

Authors:  A I Vinik; W E Strodel; F E Eckhauser; A R Moattari; R Lloyd
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

Review 2.  Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment.

Authors:  E Mozell; P Stenzel; E A Woltering; J Rösch; T M O'Dorisio
Journal:  Curr Probl Surg       Date:  1990-06       Impact factor: 1.909

3.  Periampullary pancreatic somatostatinoma.

Authors:  Michael G House; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg Oncol       Date:  2002-11       Impact factor: 5.344

4.  Pancreatic somatostatinoma.

Authors:  S Sakazaki; K Umeyama; H Nakagawa; H Hashimoto; K Kamino; T Mitsuhashi; K Yamaguchi
Journal:  Am J Surg       Date:  1983-11       Impact factor: 2.565

5.  Strategy for pancreatic endocrine tumors.

Authors:  T Sato; K Konishi; H Kimura; K Maeda; K Yabushita; M Tsuji; H Demachi; A Miwa
Journal:  Hepatogastroenterology       Date:  2000 Mar-Apr

6.  Imaging features of somatostatinoma: MR, CT, US, and angiography.

Authors:  R T Tjon A Tham; J B Jansen; T H Falke; C B Lamers
Journal:  J Comput Assist Tomogr       Date:  1994 May-Jun       Impact factor: 1.826

Review 7.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

8.  Somatostatinoma: atypical presentation of a rare pancreatic tumor.

Authors:  C Anene; J S Thompson; J Saigh; S Badakhsh; R E Ecklund
Journal:  Am J Gastroenterol       Date:  1995-05       Impact factor: 10.864

9.  Pancreatic somatostatinoma. Clinical features and physiological implications.

Authors:  L I Larsson; M A Hirsch; J J Holst; S Ingemansson; C Kühl; S L Jensen; G Lundqvist; J F Rehfeld; T W Schwartz
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

Review 10.  Pancreatic somatostatinoma: a case report and review of the literature.

Authors:  K Konomi; K Chijiiwa; T Katsuta; K Yamaguchi
Journal:  J Surg Oncol       Date:  1990-04       Impact factor: 3.454

View more
  2 in total

1.  Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Eleni Papoutsi; Vasiliki Ntella; Prodromos Kanavidis; Athanasios Sioulas; Marina Tsoli; Georgios Charalampopoulos; Michail Vailas; Evangelos Felekouras
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Gastric somatostatinoma: an extremely rare cause of upper gastrointestinal bleeding.

Authors:  Varayu Prachayakul; Pitulak Aswakul; Morakod Deesomsak; Ananya Pongpaibul
Journal:  Clin Endosc       Date:  2013-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.